| PubMed:Characterization of physical and chemical defenses in the hemlock woolly adelgid. |
| PubMed:A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling. |
| PubMed:Proteomic and pathway analyses reveal a network of inflammatory genes associated with differences in skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. |
| PubMed:Potential feeding deterrents found in hemlock woolly adelgid, Adelges tsugae. |
| PubMed:Cassia occidentalis L.: a review on its ethnobotany, phytochemical and pharmacological profile. |
| PubMed:Activation of epidermal akt by diverse mouse skin tumor promoters. |
| PubMed:Anthraquinones as defensive compounds in eggs of Galerucini leaf beetles: biosynthesis by the beetles? |
| PubMed:Defensive components in insect eggs: are anthraquinones produced during egg development? |
| PubMed:Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. |
| PubMed:Overexpression of a dominant-negative ornithine decarboxylase in mouse skin: effect on enzyme activity and papilloma formation. |
| PubMed:Collagenase induction promotes mouse tumorigenesis by two independent pathways. |
| PubMed:Skin tumorigenesis by initiators and promoters of different chemical structures in lines of mice selectively bred for resistance (Car-r) or susceptibility (Car-s) to two-stage skin carcinogenesis. |
| PubMed:Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. |
| PubMed:Alterations in cholesterol sulfate and its biosynthetic enzyme during multistage carcinogenesis in mouse skin. |
| PubMed:Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol. |
| PubMed:Inhibition of the glucocorticoid receptor expression by diverse tumor promoters in SENCAR mouse epidermis. |
| PubMed:Induction or suppression of SV40 amplification by genotoxic carcinogens, non-genotoxic carcinogens or tumor promoters. |
| PubMed:Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. |
| PubMed:Effect of diverse tumor promoters on the expression of gap-junctional proteins connexin (Cx)26, Cx31.1, and Cx43 in SENCAR mouse epidermis. |
| PubMed:The effects of calcium antagonists on anthrone skin tumor promotion and promoter-related effects in SENCAR mice. |
| PubMed:Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice. |
| PubMed:Elevation of transforming growth factor-alpha mRNA and protein expression by diverse tumor promoters in SENCAR mouse epidermis. |
| PubMed:Genetic factors controlling responsiveness to skin tumor promotion in mice. |
| PubMed:Skin carcinogenesis: characteristics, mechanisms, and prevention. |
| PubMed:Loss of mouse epidermal protein kinase C isozyme activities following treatment with phorbol ester and non-phorbol ester tumor promoters. |
| PubMed:An EPR study of free radicals formed by antipsoriatic and tumor-promoting 9-anthrones in nonpolar solvents. |
| PubMed:Toxicity of structurally related anthraquinones and anthrones to mammalian cells in vitro. |
| PubMed:Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition. |
| PubMed:Dose-response relationship in multistage carcinogenesis: promoters. |
| PubMed:Polarographic and absorptive stripping voltammetric determination of mitoxantrone, emodin and chrysarobin using mercury and glassy carbon electrodes. |
| PubMed:Inhibition of chrysarobin skin tumor promotion in SENCAR mice by antioxidants. |
| PubMed:Further studies on the influence of initiation dose on papilloma growth and progression during two-stage carcinogenesis in SENCAR mice. |
| PubMed:History of the treatment of psoriasis. |
| PubMed:Anthralin, a non-TPA type tumor promoter, synergistically enhances phorbol ester-caused prostaglandin E2 release from primary cultured mouse epidermal cells. |
| PubMed:Phorbol ester-mediated suppression of cytochrome P450 Cyp1a-1 induction in murine skin: involvement of protein kinase C. |
| PubMed:[The tree, from which chrysarobin was isolated]. |
| PubMed:Enhanced induction of epidermal ornithine decarboxylase activity in C57BL/6 compared to DBA/2 mice by protein kinase C-activating skin tumor promoters: relevance to genetically mediated differences in promotion susceptibility. |
| PubMed:[75 years of Cignolin]. |
| PubMed:Evidence for a common genetic pathway controlling susceptibility to mouse skin tumor promotion by diverse classes of promoting agents. |
| PubMed:Evidence for autocrine/paracrine growth stimulation by transforming growth factor-alpha during the process of skin tumor promotion. |
| PubMed:Malignant conversion, the first stage in progression, is distinct from phorbol ester promotion in mouse skin. |
| PubMed:Differential mechanism for the inhibition of epidermal growth factor binding to its receptor on mouse keratinocytes by anthrones and phorbol esters. |
| PubMed:Differential effects of various skin tumor-promoting agents on prostaglandin E2 release from primary cultures of mouse epidermal cells. |
| PubMed:[Chemical instability of the antipsoriatic dithranol and chrysarobin in aqueous systems: oxidation behavior]. |
| PubMed:[Synthesis, characterization, racemation and biochemical studies on 10-acylderivatives of chrysarobin: sorbylchrysarobin, beta-carbethoxypropionylchrysarobin and senecioylchrysarobin]. |
| PubMed:[Purification, glucose-6-phosphate dehydrogenase inhibition, and HPLC analysis of four 1,8-dihydroxyanthrones]. |
| PubMed:[The history of dermatology. On the 150th birthday of Heinrich Köbner]. |
| PubMed:Histologic alterations produced by chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) in SENCAR mouse skin: relationship to skin tumor promoting activity. |
| PubMed:Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type. |
| PubMed:Alterations in epidermal polyamine levels and DNA synthesis following topical treatment with chrysarobin in SENCAR mice. |
| PubMed:Presence of a functionally altered ornithine decarboxylase activity in chrysarobin-promoted mouse epidermal papillomas. |
| PubMed:Structure-activity relationships for epidermal ornithine decarboxylase induction and skin tumor promotion by anthrones. |
| PubMed:Modulation of chrysarobin skin tumor promotion. |
| PubMed:Enhancement of mezerein-promoted papilloma formation by treatment with 12-O-tetradecanoylphorbol-13-acetate or mezerein prior to initiation. |
| PubMed:Comparison of the histological changes in the skin of DBA/2 and C57BL/6 mice following exposure to various promoting agents. |
| PubMed:Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice. |
| PubMed:Effect of application frequency on epidermal ornithine decarboxylase induction by chrysarobin in SENCAR mice. |
| PubMed:Mechanism of mouse skin tumor promotion by chrysarobin. |
| PubMed:Anthralin: historical and current perspectives. |
| PubMed:Tumor promoting activity of 1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin) in female SENCAR mice. |
| PubMed:Anthralin and chrysarobin: a reexamination of the origins and early use. |
| PubMed:Structure specificity of the antipsoriatic anthrones. |
| PubMed:[Zonal psoriasis]. |
| PubMed:On the molecular structure of some prostaglandin receptors. |
| PubMed:[Introduction of chrysarobin into Europe. A contribution to the history of dermatotherapy]. |
| PubMed:Thin-layer chromatographic separation and identification of the main constituents of Chrysarobin. |
| PubMed:[Investigations on the mechanism of action of chrysarobin and dithranol (=Cignolin) in psoriasis. Indications for a cytostatic action of these drugs]. |
| PubMed:PSORIASIS; A STATISTICAL STUDY OF THE GOECKERMAN AND THE CHRYSAROBIN THERAPIES, AND OF VARIOUS FACTORS INFLUENCING THE CLINIC. |
| PubMed:[Experimental studies of the mechanism of action of chrysarobin and dithranol in psoriasis (evidence for a cytostatic effect on the epidermis)]. |
| PubMed:[ATTEMPT AT STANDARDIZATION OF CHRYSAROBIN WITH TUBIFEX]. |
| PubMed:[ON PRODUCTION OF A PREPARATION SIMILAR TO CHRYSAROBIN FROM RHEUM PALMATUM VAR. TANGUTICUM MAXIM]. |
| PubMed:[On the utilization of natural resources for chrysarobin production]. |
| PubMed:Chloranil in the treatment of psoriasis; a substitute for chrysarobin. |
| PubMed:Remarks on chronic seborrheic dermatitis of the external ear with special reference to treatment with chrysarobin. |
| PubMed:[Our experience with chrysarobin therapy in very weak concentrations]. |
| PubMed:[Pharmacology of chrysarobin]. |
| PubMed:Case of Unusual Tolerance in Chrysarobin. |
| PubMed:Deductions from Three Hundred and Nineteen Observations of the Action of Chrysarobin-a New Emeticpurge. |
| PubMed:Anthralin/dithranol in dermatology. |